Clinical Trial Update: Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating a birth dose of GlaxoSmithKline's 251154 rotavirus vaccine has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• 251154 vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 2 | Status: WITHDRAWN